MedTrace Logo

An Open-Label Feasibility/Pilot Study With [123I]-IBZM SPECT (DOPA-SYN)

NCT00200447 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2008-01-21

No results posted yet for this study

Summary

This study conducted to more fully evaluate the way that carbidopa/levodopa and entacapone may work in the brain. This research study uses \[123I\]-IBZM and dynamic SPECT imaging to determine the amount and the duration of dopamine release from specific regions in the brain after treatment with either the combination of carbidopa/levodopa or the combination of carbidopa/levodopa/entacapone.

Conditions

Interventions

DRUG

carbidopa/l-dopa

DRUG

carbidopa/l-dopa/entacapone

DRUG

Stalevo

PROCEDURE

[123I]-IBZM imaging

Sponsors & Collaborators

  • Molecular NeuroImaging

    lead OTHER

Principal Investigators

  • John P Seibyl, MD · Molecular NeuroImaging

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-03-31
Primary Completion
2004-09-30
Completion
2004-09-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00200447 on ClinicalTrials.gov